1FDA. Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment[EB/OL]. (2005-03-22) [2015-05-12].www.fda.gov/downloads/Regulatorylnformation/ Guidances/UCM126834.pdf.
2Pfizer Ltd.Safety of medicines[EB/OL].(2015-03-O1)[2015-05-12]. http://www.pfizer.co.uk/content/safety-medicines.
4Hammond I W, Gibbs T G, Seifert H A, et al. Database size and power to detect safety signals in pharmacovigilance[J]. Expert opinion on drug safety, 2007, 6(6): 715-721.
5Van Holle L, Bauchau V. Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time- to-onset-based algorithm [J]. Pharmacoepidemiology and Drug Safety, 2014, 23(2): 178-185.
6Candore G, Juhlin K, Manlik K, et al. Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases[J]. Drug Safety, 2015,38(6):577-587.
7ARISGLOBAL. ARISg^TM. The Drug Safety Software Most Used by Pharmaceutical Companies [EB/OL]. (2015-03-15) [2015-05-12]. http://arisglobal.com/total-safety/arisg/.
8SAYERS J. Implementing a quality management system in a global pharmacovigilance processing centre[J]. The Quality Assurance Journal, 2001, 5(2): 71-75.
9Camberidge Healthtech. 2010 Best Practices Competition Basic ResearchandDrugDiscovery[EB/OL].(2010-06-15).[2015-05-12].www.chicorporate.com/uploadedfiles/bio-it_world/best practices/ 2010/md-comp.pdf.
